Pamela Vig

2.9k total citations
45 papers, 1.5k citations indexed

About

Pamela Vig is a scholar working on Hepatology, Surgery and Epidemiology. According to data from OpenAlex, Pamela Vig has authored 45 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hepatology, 23 papers in Surgery and 15 papers in Epidemiology. Recurrent topics in Pamela Vig's work include Pediatric Hepatobiliary Diseases and Treatments (17 papers), Drug Transport and Resistance Mechanisms (13 papers) and Liver Diseases and Immunity (11 papers). Pamela Vig is often cited by papers focused on Pediatric Hepatobiliary Diseases and Treatments (17 papers), Drug Transport and Resistance Mechanisms (13 papers) and Liver Diseases and Immunity (11 papers). Pamela Vig collaborates with scholars based in United States, United Kingdom and France. Pamela Vig's co-authors include Malcolm Alison, Stuart J. Forbes, Richard Poulsom, Howard Thomas, Nicholas A. Wright, Francesco Paolo Russo, Thierry Poynard, Vincent Thibault, Carol Brosgart and Vincent Cálvez and has published in prestigious journals such as The Lancet, Hepatology and Journal of Cell Science.

In The Last Decade

Pamela Vig

41 papers receiving 1.5k citations

Peers

Pamela Vig

HEPAT

EPIDE

SURGE

ONCOL

Laura Gragnani Italy

Espen Melum Norway

Janeth C. Villanueva United States

Silvia Martina Ferrari Italy

J. C. O’Keane Ireland

Kenneth E. Drazan United States

Roman Rieger Austria

Hirokazu Kawai Japan

Chantal André France

Maxime Mallet France

Laura Gragnani Italy

Pamela Vig

1.3k ×1.5

HEPAT

829 ×1.2

EPIDE

185 ×0.4

SURGE

253 ×1.0

134 ×0.6

ONCOL

Citations per year, relative to Pamela Vig Pamela Vig (= 1×) peers Laura Gragnani

Countries citing papers authored by Pamela Vig

Since Specialization

Citations

This map shows the geographic impact of Pamela Vig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela Vig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela Vig more than expected).

Fields of papers citing papers by Pamela Vig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pamela Vig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela Vig. The network helps show where Pamela Vig may publish in the future.

Co-authorship network of co-authors of Pamela Vig

This figure shows the co-authorship network connecting the top 25 collaborators of Pamela Vig. A scholar is included among the top collaborators of Pamela Vig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela Vig. Pamela Vig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pramparo, Tiziano, et al.. (2025). Smith-Lemli-Opitz syndrome: Clinical, biochemical, and genetic insights with emerging treatment opportunities. Genetics in Medicine. 27(7). 101450–101450. 1 indexed citations

Kelly, Déirdre, Binita M. Kamath, Emmanuel Gonzalès, et al.. (2025). Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study. Digestive and Liver Disease. 57. S69–S69.

D’Antiga, Lorenzo, Richard J. Thompson, Simon Horslen, et al.. (2025). The relationship between serum bile acids and event-free survival following the use of maralixibat for progressive familial intrahepatic cholestasis: data from MARCH/MARCH-ON. Digestive and Liver Disease. 57. S67–S68.

Vandriel, Shannon M., et al.. (2025). Maralixibat Reduces Serum Bile Acids and Improves Cholestatic Pruritus in Adolescents With Alagille Syndrome. Liver International. 45(2). e16201–e16201. 2 indexed citations

Bufler, Philip, et al.. (2025). The burden of Alagille syndrome: uncovering the potential of emerging therapeutics – a comprehensive systematic literature review. Journal of Comparative Effectiveness Research. 14(2). e240188–e240188. 1 indexed citations

Bowlus, Christopher L., Bertus Eksteen, Angela Cheung, et al.. (2023). Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study. Hepatology Communications. 7(6). 22 indexed citations

Hirschfield, Gideon M., Douglas Mogul, Marshall Baek, Pamela Vig, & Binita M. Kamath. (2023). Impact of maralixibat on cholestatic pruritus in adults aged 16 years and older with Alagille syndrome. Journal of Hepatology. 78. S372–S372. 1 indexed citations

Kamath, Binita M., Will Garner, Pamela Vig, et al.. (2022). Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life. The Journal of Pediatrics. 252. 68–75.e5. 15 indexed citations

Nielsen, Mette Juul, Diana Julie Leeming, Zachary Goodman, et al.. (2021). Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. Journal of Hepatology. 75(6). 1292–1300. 42 indexed citations

10.

Gonzalès, Emmanuel, Winita Hardikar, Michael Stormon, et al.. (2021). Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. The Lancet. 398(10311). 1581–1592. 103 indexed citations

11.

Eksteen, Bertus, Christopher L. Bowlus, Aldo J. Montaño‐Loza, et al.. (2020). Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study. Hepatology Communications. 5(3). 478–490. 35 indexed citations

12.

Vig, Pamela, et al.. (2020). PIH76 ITCH REPORTED OUTCOME TOOL FOR CAREGIVERS OF PEDIATRIC PATIENTS WITH CHOLESTATIC LIVER DISEASE: AN ANALYSIS OF VALIDATION AND SCORING FROM THE ICONIC MARALIXIBAT STUDY. Value in Health. 23. S166–S166. 1 indexed citations

13.

Gonzalès, Emmanuel, Ekkehard Sturm, Michael Stormon, et al.. (2019). DURABILITY OF TREATMENT EFFECT WITH LONG-TERM MARALIXIBAT IN CHILDREN WITH ALAGILLE SYNDROME: 4-YEAR SAFETY AND EFFICACY RESULTS FROM THE ICONIC STUDY. Hepatology. 70(6). 1 indexed citations

14.

Guicciardi, Maria Eugenia, Christy E. Trussoni, Anuradha Krishnan, et al.. (2018). Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice. Journal of Hepatology. 69(3). 676–686. 125 indexed citations

15.

Esmat, Gamal, Tamer Elbaz, Maissa El Raziky, et al.. (2017). Effectiveness of ravidasvir plus sofosbuvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. Journal of Hepatology. 68(1). 53–62. 12 indexed citations

16.

Vig, Pamela, Francesco Paolo Russo, Robert J. Edwards, et al.. (2006). The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. Hepatology. 43(2). 316–324. 88 indexed citations

17.

Alison, Malcolm, Pamela Vig, Francesco Paolo Russo, et al.. (2004). Hepatic stem cells: from inside and outside the liver?. Cell Proliferation. 37(1). 1–21. 114 indexed citations

18.

Forbes, Stuart J., Pamela Vig, Richard Poulsom, Howard Thomas, & Malcolm Alison. (2002). Hepatic stem cells. The Journal of Pathology. 197(4). 510–518. 147 indexed citations

19.

Benhamou, Y., Vincent Thibault, Vincent Cálvez, et al.. (2001). Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study. The Lancet. 358(9283). 718–723. 221 indexed citations

20.

Emery, Sean, William B. Capra, David A. Cooper, et al.. (2000). Pooled Analysis of 3 Randomized, Controlled Trials of Interleukin‐2 Therapy in Adult Human Immunodeficiency Virus Type 1 Disease. The Journal of Infectious Diseases. 182(2). 428–434. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact